{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:49:44Z","timestamp":1774464584968,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T00:00:00Z","timestamp":1266278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic>\u2002<jats:bold>31<\/jats:bold>, 1018\u20131027<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Chronic infection with hepatitis C, genotype 2\/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of peginterferon would be as effective, but less toxic than standard doses.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To test the hypothesis that a lower dose of peginterferon would be as effective as, but less toxic than, standard doses.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 30 patients were treated with low\u2010dose peginterferon alfa\u20102a (90\u2003\u03bcg\/week) and 27 patients with standard doses (180\u2003\u03bcg\/week) for 24\u2003weeks in combination with 800\u2003mg\/day of ribavirin. Patients who failed treatment were offered 48\u2003weeks of standard\u2010dose treatment. Viral and serum inducible protein 10 (IP\u201010) levels were measured and early viral kinetic parameters were calculated.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Sustained virological response was achieved in 68% of the low\u2010dose and 87% of the standard\u2010dose patients (per protocol, <jats:italic>P<\/jats:italic>\u2003=\u20030.79 for non\u2010inferiority). Re\u2010treatment was successful in all patients who tolerated full dose and duration. The standard\u2010dose group had greater first\u2010phase declines of viral levels and faster time to negativity. The second\u2010phase slope was not dose\u2010dependent. IP\u201010 induction was significantly greater with the standard dose. Although fatigue and general feeling during treatment were worse for standard dose, haematological toxicity and depression did not differ between groups.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> A lower dose of peginterferon is associated with some symptomatic benefit, but the response is not equivalent to standard dosing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04263.x","type":"journal-article","created":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T12:23:03Z","timestamp":1266322983000},"page":"1018-1027","source":"Crossref","is-referenced-by-count":7,"title":["Low\u2010 and standard\u2010dose peginterferon alfa\u20102a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response"],"prefix":"10.1111","volume":"31","author":[{"given":"Y.","family":"ROTMAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. B.","family":"BORG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"SOZA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"FELD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"MODI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"LOOMBA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"LUTCHMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"RIVERA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"DOO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"GHANY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"HELLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. U.","family":"NEUMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"LIANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"HOOFNAGLE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,5]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Annual Meeting of the Infectious Diseases Society of America","author":"Perz JF","year":"2004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-007-2064-6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70234-8"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03763.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30306.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5386.103"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.059"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02640-06"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707882105"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21853"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074062"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21407"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/507307"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/014662167700100306"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24006"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2307\/2529457"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.015"},{"key":"e_1_2_6_24_2","volume-title":"AASLD Liver Meeting","author":"Feld JJ","year":"2008"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05057.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00709.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00614.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21747"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00768.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.00999.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32150"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04263.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04263.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:22:22Z","timestamp":1698783742000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04263.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,5]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04263.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04263.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,5]]}}}